We are live on ! Find out more
OMGA

Omega Therapeutics, Inc. Common Stock
OMGA

Delisted

OMGA was delisted on the 24th of February, 2025.

Back to rankings

54 hedge funds and large institutions have $59M invested in Omega Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $33K | Put options by funds: $11K

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

21% less funds holding

Funds holding: 68 → 54 (-14)

44% less capital invested

Capital invested by funds: $105M → $59M (-$45.7M)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

70% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 20

Holders
54
Holders Change
-14
Holders Change %
-20.59%
% of All Funds
0.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
7
Reduced
15
Closed
20
Calls
$33K
Puts
$11K
Net Calls
+$22K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$551K
2
GAA
Green Alpha Advisors
Colorado
+$99.6K
3
Pathstone Holdings
Pathstone Holdings
New Jersey
+$64.9K
4
RJFSA
Raymond James Financial Services Advisors
Florida
+$33.9K
5
FIM
Freedom Investment Management
Connecticut
+$20K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.74M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.64M
3
Jane Street
Jane Street
New York
-$442K
4
Goldman Sachs
Goldman Sachs
New York
-$394K
5
Millennium Management
Millennium Management
New York
-$348K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$48.4K -$199K -125,068 -76%
MG
27
Marex Group
$44K – – –
XT
28
XTX Topco
Cayman Islands
$39.3K -$82.3K -51,686 -62%
CSS
29
Cubist Systematic Strategies
Connecticut
$38.6K – – –
Wells Fargo
30
Wells Fargo
California
$28.6K – – –
Squarepoint
31
Squarepoint
New York
$22.2K -$325K -204,233 -92%
Bank of America
32
Bank of America
North Carolina
$20.2K +$9.77K +6,137 +59%
MPAM
33
Murphy Pohlad Asset Management
Minnesota
$20.1K – – –
C
34
Certuity
Florida
$18.3K +$7.96K +5,000 +50%
Barclays
35
Barclays
United Kingdom
$16.2K -$285 -179 -1%
FIM
36
Freedom Investment Management
Connecticut
$15.3K +$20K +12,538 New
CFM
37
Catalyst Funds Management
Australia
$7.44K – – –
SPIA
38
Steward Partners Investment Advisory
New York
$6.1K +$4.78K +3,000 +150%
TRCT
39
Tower Research Capital (TRC)
New York
$5.58K -$11.9K -7,449 -62%
Group One Trading
40
Group One Trading
Illinois
$4.22K – – –
UBS Group
41
UBS Group
Switzerland
$3.65K +$2.46K +1,545 +107%
PS
42
Principal Securities
Iowa
$1.67K +$2.18K +1,370 New
AWM
43
AllSquare Wealth Management
New York
$1.22K – – –
PD
44
Point72 (DIFC)
United Arab Emirates
$1.16K – – –
Simplex Trading
45
Simplex Trading
Illinois
$1K +$2.4K +1,509 New
SSB
46
Sandy Spring Bank
Maryland
$915 – – –
JP Morgan Chase
47
JP Morgan Chase
New York
$614 -$2 -1 -0.2%
HI
48
Harbour Investments
Wisconsin
$336 – – –
Osaic Holdings
49
Osaic Holdings
Arizona
$244 – – –
AAP
50
Arax Advisory Partners
Colorado
$66 – – –
1
2
3

OMGA Hedge Fund Activity: Q3 2024 in Review

54 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q3 2024, worth a combined $59M — down 44% from $105M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of OMGA and 6 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $551K. The largest seller was Artal Group, exiting entirely with an estimated $2.74M sold.

  • 54 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q3 2024, down from 68 in Q2 2024.
  • Funds reported $59M of Omega Therapeutics, Inc. Common Stock stock for Q3 2024, down 44% quarter-over-quarter.
  • 6 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q3 2024 and 20 closed out, a net change of -14 holders.
  • The largest Omega Therapeutics, Inc. Common Stock buyer in Q3 2024 was Renaissance Technologies, an estimated $551K added.
  • The largest Omega Therapeutics, Inc. Common Stock seller in Q3 2024 was Artal Group, an estimated $2.74M sold.

Based on aggregated 13F filings for Q3 2024.